Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC102 versus oral prednisolone for idiopathic sudden sensorineural hearing loss
NL-OMON56096Phase 2Recruiting
- Sponsor
- AudioCure Pharma GmbH
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AC102 and prednisolone in idiopathic sudden sensorineural hearing loss (ISSNHL) (2 arms), sponsored by AudioCure Pharma GmbH. Primary endpoint: Mean change in hearing threshold at Day 28. Started Jul 2023; status: recruiting.
02
Drugs
AC102prednisolone
03
Conditions
idiopathic sudden sensorineural hearing loss (ISSNHL)
Beyond the preview
Go deeper on NL-OMON56096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56096.